南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2014年
2期
270-274
,共5页
恩度%晚期结直肠癌%meta分析%随机对照实验
恩度%晚期結直腸癌%meta分析%隨機對照實驗
은도%만기결직장암%meta분석%수궤대조실험
Endostar%advanced colorectal cancer%meta-analysis%randomized controlled trials
目的：系统评价恩度联合化疗治疗晚期结直肠癌的有效性和安全性。方法计算机检索Cochrane图书馆、PubMed、Embase、CNKI、CBM、VIP，中华医学会数字化期刊。检索年限均为建库至2013年1月。按Cochrane系统评价员手册对纳入文献的方法学质量进行评价后，提取数据，采用RevMan 5.2统计软件行Meta分析。结果共纳入5个随机对照试验，包括220例病例。Meta分析结果显示恩度联合化疗较单纯化疗而言，其疾病的恩度联合化疗组的CR（10.91%vs 2.73%，RR=4.08，95%CI：1.19-13.95，P=0.02）、PR（48.18%vs 30.91%，RR=2.18，95%CI：1.23-3.87，P=0.007）、PD（15.45%vs 41.82%，RR=0.25，95%CI：0.13-0.47，P<0.0001）、RR（60.00%vs 33.64%，RR=3.23，95%CI：1.79-5.81，P<0.0001）、CBR（82.73%vs 55.45%，RR=4.30，95%CI：1.19-13.95，P<0.0001）方面均显示出优势。恩度的主要不良反应包括恶心、呕吐、便秘、心慌、心电图改变等。结论恩度联合化疗对于晚期结直肠癌疗效较好，恩度联合化疗药物可作为治疗晚期结直肠癌的常规药物。
目的：繫統評價恩度聯閤化療治療晚期結直腸癌的有效性和安全性。方法計算機檢索Cochrane圖書館、PubMed、Embase、CNKI、CBM、VIP，中華醫學會數字化期刊。檢索年限均為建庫至2013年1月。按Cochrane繫統評價員手冊對納入文獻的方法學質量進行評價後，提取數據，採用RevMan 5.2統計軟件行Meta分析。結果共納入5箇隨機對照試驗，包括220例病例。Meta分析結果顯示恩度聯閤化療較單純化療而言，其疾病的恩度聯閤化療組的CR（10.91%vs 2.73%，RR=4.08，95%CI：1.19-13.95，P=0.02）、PR（48.18%vs 30.91%，RR=2.18，95%CI：1.23-3.87，P=0.007）、PD（15.45%vs 41.82%，RR=0.25，95%CI：0.13-0.47，P<0.0001）、RR（60.00%vs 33.64%，RR=3.23，95%CI：1.79-5.81，P<0.0001）、CBR（82.73%vs 55.45%，RR=4.30，95%CI：1.19-13.95，P<0.0001）方麵均顯示齣優勢。恩度的主要不良反應包括噁心、嘔吐、便祕、心慌、心電圖改變等。結論恩度聯閤化療對于晚期結直腸癌療效較好，恩度聯閤化療藥物可作為治療晚期結直腸癌的常規藥物。
목적：계통평개은도연합화료치료만기결직장암적유효성화안전성。방법계산궤검색Cochrane도서관、PubMed、Embase、CNKI、CBM、VIP，중화의학회수자화기간。검색년한균위건고지2013년1월。안Cochrane계통평개원수책대납입문헌적방법학질량진행평개후，제취수거，채용RevMan 5.2통계연건행Meta분석。결과공납입5개수궤대조시험，포괄220례병례。Meta분석결과현시은도연합화료교단순화료이언，기질병적은도연합화료조적CR（10.91%vs 2.73%，RR=4.08，95%CI：1.19-13.95，P=0.02）、PR（48.18%vs 30.91%，RR=2.18，95%CI：1.23-3.87，P=0.007）、PD（15.45%vs 41.82%，RR=0.25，95%CI：0.13-0.47，P<0.0001）、RR（60.00%vs 33.64%，RR=3.23，95%CI：1.79-5.81，P<0.0001）、CBR（82.73%vs 55.45%，RR=4.30，95%CI：1.19-13.95，P<0.0001）방면균현시출우세。은도적주요불량반응포괄악심、구토、편비、심황、심전도개변등。결론은도연합화료대우만기결직장암료효교호，은도연합화료약물가작위치료만기결직장암적상규약물。
Objective To evaluate the safety and efficacy of Endostar combined with chemotherapy in the treatment of end-stage colorectal cancer. Methods The relevant randomized controlled trials were retrieved from the electronic databases of Cochrane library, PubMed, EMbase, CNKI, CBM, VIP and Chinese Medical Association. The retrieval time limit was from the database construction to January 2013. The data were extracted from eligible studies assessed for methodological quality according to Cochrane handbook for systematic reviews and analyzed using RevMan 5.2 software. Results Five randomized controlled trials involving 220 cases were included for meta-analysis. The results showed that Endostar combined with chemotherapy had an overall advantage over chemotherapy alone in terms of complete response rate (10.91%vs 2.73%RR=4.08, 95%CI:1.19-13.95, P=0.02), partial response rate (48.18% vs 30.91% RR=2.18, 95% CI: 1.23-3.87, P=0.007), progressive disease (15.45% vs 41.82% RR=0.25, 95% CI: 0.13-0.47, P<0.0001), and the response rate (60.00% vs 33.64% RR=3.23, 95% CI: 1.79-5.81, P<0.0001). Clinical benefit response(82.73%vs 55.45%RR=4.30,95%CI:1.19-13.95, P<0.0001). The main adverse reactions included nausea, vomiting, constipation, palpitation, and electrocardiogram changes. Conclusion Endostar combined with chemotherapy is effective for advanced colorectal cancer and can be used as a routine treatment.
